Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

First Guidelines Focused Specifically on Chest Pain Management

Many years of developing and waiting have led us to the latest guidelines published by ACC/AHA together with other societies. This is the first document exclusively dedicated to the assessment and diagnosis of acute chest pain. In this regard, we can safely say this is no mere update of a previous set of guidelines, but an original study written from scratch. 

manejo del dolor precordial

These guidelines incorporate the use of contemporary cardiac images which include coronary computed tomography angiography (CCTA) and coronary artery calcium testing. They also call for selective use of imaging and, of course, detail the factors to take into account when choosing between CCTA and a stress test. 

These guidelines also emphasize that chest pain might also be experienced without pressure, tightness, or discomfort, and it might also be felt on shoulders, arms, neck, back, upper abdomen or jaw. Fatigue, shortness of breath and nausea should also be taken into account, particularly in women. 

Ultrasensitive troponin are now the standard biomarkers for MI diagnosis. Others such as CK, Mb or total CK should be abandoned. 

Patients admitted to the ER with chest pain and suspect acute coronary syndrome should be classified into low, intermediate, and high risk. 

For intermediate risk patients with no known CAD, CCTA is recommended, to exclude CAD (class I level A). 

If there was evidence of stenosis or the CT scan was not conclusive, functional flow reserve computed tomography (FFR-CT) can be used on a specific vessel, to clear any doubts. 


Read also: Fluoroscopy vs. Ultrasound Guided Femoral Access in TAVR.


For intermediate risk patients, it also has a class I recommendation: a stress test with evidence level B. 

For high-risk patients, it has a class I recommendation: an invasive angiography.

Patients al low risk, those with a 30-day risk of death or events lower than 1%, can be sent home with guidelines for them to watch for symptoms.


Read also: 10 Years Treating Bifurcations: Have We Made Progress?


Another change introduced by this study is removing the word “atypical” from the description and replacing it with “non-cardiac cause” when cardiac causes have been ruled out. 

One other additional contribution of these guidelines is minimizing unnecessary studies which will eventually guarantee an event-free period in patients with chest pain. When both regular angiographies and CCTA do not show stenosis or plaque, there is a 2-year guarantee, while a normal stress test offers just one year.

Original Title: AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee of clinical practice guidelines.

Reference: Gulati M et al. Circulation. 2021 Oct 28;CIR0000000000001029. Online ahead of print. doi: 10.1161/CIR.0000000000001029. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...